My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

30.55 -0.15 (-0.49%)

Streaming Delayed Price Updated: 12:41 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm

August 02, 2022

From The Schall Law Firm

Via Business Wire

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

Why Is Target (TGT) Stock in the Spotlight Today? ↗

August 01, 2022

Target (TGT) stock is in the news today as investors react to a new note from Jefferies that gives the retail company flak.

Via InvestorPlace

Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News ↗

August 01, 2022

Beam Therapeutics (BEAM) stock is slipping on Monday after the U.S. Food and Drug Administration placed a clinical hold on one of its drugs.

Via InvestorPlace

FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses ↗

August 01, 2022

The company didn't identify the reason behind the clinical hold in cancer treatment.

Via Investor's Business Daily

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success ↗

June 17, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 08, 2022

During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap...

Via Benzinga

Expert Ratings For Beam Therapeutics ↗

January 10, 2022

Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the f...

Via Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial ↗

August 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 01, 2022

Via Benzinga

Beam Therapeutics Shares Decline Following FDA's Clinical Hold On Leukemia Study ↗

August 01, 2022

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Beam Therapeutics’ (NASDAQ: BEAM) Investigational New Drug (IND) application for the candidate BEAM-201 in the treatment of...

Via Benzinga

Will a Recession Cause a Housing Crash in 2022? ↗

July 27, 2022

For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 26, 2022

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 20, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗

July 20, 2022

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...

Via Benzinga

Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage ↗

July 18, 2022

Via Benzinga

Hold Pfizer Today With Catalysts for Further Growth Tomorrow

July 18, 2022

Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives.

Via MarketBeat

The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol ↗

July 12, 2022

This could offer an improvement over CRISPR, which requires cutting DNA.

Via Investor's Business Daily

The 3 Leaders of the Gene Editing Revolution ↗

July 08, 2022

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.

Via InvestorPlace

7 Moonshot Investments Upending a $10 Trillion Industry ↗

July 08, 2022

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.

Via InvestorPlace

Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics ↗

July 07, 2022

Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ:

Via Benzinga

Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit? ↗

July 05, 2022

The FDA's advisors recently backed Pfizer's Covid shot for young children.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗

January 14, 2022

A rebound from Monday's lows faded, with the key indexes all down for the week.

Via Investor's Business Daily

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

Pfizer Continues Its Covid Makeover: What's Next For This Hot Stock? ↗

January 13, 2022

How the pandemic continued a transformation Pfizer says began years ago.

Via Investor's Business Daily

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs ↗

January 10, 2022

Pfizer Inc (NYSE: PFE) and Beam Therapeutics Inc (NASDAQ: BEAM) have announced an exclusive four-year research collaboration focused on in vivo ...

Via Benzinga

Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗

January 10, 2022

The companies hope to cure diseases of the liver, muscle and central nervous system.

Via Investor's Business Daily

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.